Evidence map›Paper›PMID 42177854›Full record

ArticleClinics (Sao Paulo, Brazil)2026

Allergen-specific immunotherapy in rhinitis patients is associated with milder COVID-19 symptoms and improved quality of life.

Hanqiao Li, Renkang Wang, Benquan Yu, Jun He, Yibo Hu, Zuozhong Xie, Zi'an Xiao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hanqiao LiDepartment of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China; Institute of Otology, Central South University, Changsha, Hunan Province, China; Laboratory of Otolaryngology Head and Neck Cancer, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China. Electronic address: liqiaoqiao0916@163.com.
Renkang WangDepartment of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China; Institute of Otology, Central South University, Changsha, Hunan Province, China; Laboratory of Otolaryngology Head and Neck Cancer, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China. Electronic address: wangrenkangent@163.com.
Benquan YuDepartment of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China; Institute of Otology, Central South University, Changsha, Hunan Province, China; Laboratory of Otolaryngology Head and Neck Cancer, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China. Electronic address: yubenquan8077@163.com.
Jun HeDepartment of Otolaryngology Head and Neck Surgery, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: he05@stanford.edu.
Yibo HuClinical Research Center, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address: huyibo124@163.com.
Zuozhong XieDepartment of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China; Institute of Otology, Central South University, Changsha, Hunan Province, China; Laboratory of Otolaryngology Head and Neck Cancer, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China. Electronic address: zuozhongxie@csu.edu.cn.
Zi'an XiaoDepartment of Otolaryngology Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China; Institute of Otology, Central South University, Changsha, Hunan Province, China; Laboratory of Otolaryngology Head and Neck Cancer, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China. Electronic address: xiaozian@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis retrospective study investigated the impact of Allergic Rhinitis (AR) patients receiving Allergen-specific Immunotherapy (AIT) on Coronavirus Disease 2019 (COVID-19) infection, clinical characteristics, and prognosis.

methodsThis was a single-center, retrospective cohort study that included patients with AR who received subcutaneous desensitization with Aloege or sublingual desensitization from 10 December to 31 March 2023 at Changsha The Second Xiangya Hospital, China.

resultsThe investigation comprised 761 outpatients, including 336 individuals with allergic rhinitis who underwent AIT and 425 healthy subjects. Patients with AR who received AIT treatment showed a significantly lower risk of COVID-19 infection in the multivariate analysis (OR=0.48, p = 0.005). The probability of developing hyposmia after contracting COVID-19 was reduced in the experimental cohort compared to the control cohort (OR = 0.39, 95 % CI 0.27‒0.57, p < 0.001). Additionally, the test group experienced a reduction in sore throat (OR = 0.32, 95 % CI 0.22‒0.47, p < 0.001) and a shorter duration of systemic symptoms (OR = 0.49, 95 % CI 0.34‒0.7, p < 0.001) following COVID-19 infection. Furthermore, it was discovered that the impact on quality of life after COVID-19 infection was significantly different between the two groups, with the test group exhibiting a higher quality of life compared to the control group (p < 0.001).

conclusionDuring a concentrated or sudden outbreak of COVID-19, patients with AR who received AIT had a lower proportion of hyposmia than the healthy population, and the severity of sore throat and its impact on quality of life were relatively mild.

Indexed as

Allergen-specific immunotherapyAllergic rhinitisClinical characteristicsCOVID-19Prognosis

Identifiers

PMID42177854
PMCPMC13224361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.